Yadav S, Mathew R, Sahu AK, et al. - Researchers conducted a prospective observational study including chemotherapy-induced febrile neutropenia (FN) in hematologic or solid malignancy with the aim to compare the performance of Multinational Association of Supportive Care in Cancer (MASCC) score with procalcitonin (PCT) in predicting adverse outcomes in patients with FN. The patients were assessed for the MASCC score, PCT levels, and blood cultures at the first point of contact, and treatment was performed according to routine institutional protocol. Of 100 recruited patients, 92 had hematologic malignancy and 8 had solid malignancy. Findings suggest the utility of PCT as marker with better prognostic efficacy than MASCC score in patients with FN and indicate it as useful as an adjunct to the score in risk-stratifying patients with FN.